Utility of the Growth Differentiation Factor-15 in the Differential Diagnosis of Follicular-Patterned Lesions of the Thyroid on Cytopathologic and Histopathologic Samples.

fine-needle aspiration follicular adenoma follicular carcinoma follicular hyperplasia follicular pattern follicular variant gdf-15 papillary carcinoma the bethesda system thyroid

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Sep 2023
Historique:
accepted: 28 09 2023
medline: 31 10 2023
pubmed: 31 10 2023
entrez: 31 10 2023
Statut: epublish

Résumé

Background Follicular-patterned lesions are a major gray zone in thyroid cytopathology. The recently introduced 2022 World Health Organization (WHO) classification emphasizes the importance of genetic alterations in thyroid neoplasms with the introduction of certain newer terminologies that are expected to cause remarkable changes in cytopathologic and histopathologic reporting. Although molecular assays such as the Afirma gene expression classifier and the ThyroSeq are already in use, there has been an ongoing search for further reliable molecular markers. The growth differentiation factor-15 (GDF-15) is one among them. This study aimed to determine the diagnostic utility of GDF-15 mRNA expression in frozen tissue and fine-needle aspiration (FNA) samples from follicular-patterned thyroid lesions and neoplasms. Methodology The real-time quantitative polymerase chain reaction was performed on 75 frozen tissue and FNA samples each from 19 cases of follicular thyroid hyperplasia (FTH), 10 nodular goiters (NGs), 17 follicular thyroid adenomas (FTAs), eight follicular thyroid carcinomas (FTCs), 12 follicular variant of papillary thyroid carcinomas (FVPTCs), and nine classic papillary thyroid carcinomas (CPTCs) that were diagnosed according to the 2017 WHO classification of thyroid neoplasms. The GDF-15 mRNA expression in all these cases was assessed and compared with the control thyroid tissue samples. One-way analysis of variance and the Kruskal-Wallis test were performed using GraphPad Prism 8 software to determine the significance of differences in the GDF-15 mRNA levels among various thyroid lesions. Results A higher GDF-15 mRNA expression was noted in the malignant thyroid neoplasms including FTC, FVPTC, and CPTC in comparison to FTA, with a fold change between the malignant and benign groups being more than 244.18 times. A difference in the fold change was noted between FTH and FTA with an increase in GDF-15 mRNA level in the latter, which was statistically not significant. Conclusions The fact that GDF-15 mRNA was studied both on fine-needle aspiration cytologic and the frozen tissue material and that the majority of the lesions studied were follicular-patterned establishes the GDF-15 as a potential marker not only for diagnosing malignant thyroid neoplasms of the follicular epithelium but also in distinguishing benign and malignant follicular-patterned neoplasms of the thyroid.

Identifiants

pubmed: 37905271
doi: 10.7759/cureus.46206
pmc: PMC10613452
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e46206

Informations de copyright

Copyright © 2023, Perumal et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Front Immunol. 2020 May 19;11:951
pubmed: 32508832
J Med Genet. 2004 Mar;41(3):161-70
pubmed: 14985374
J Clin Endocrinol Metab. 2010 Dec;95(12):5296-304
pubmed: 20826580
Cancer. 2008 Sep 1;113(5):930-5
pubmed: 18661512
Endocr Relat Cancer. 2007 Jun;14(2):381-91
pubmed: 17639052
Open Access Maced J Med Sci. 2018 Mar 02;6(3):435-441
pubmed: 29610597
Endocr Pathol. 2019 Mar;30(1):8-15
pubmed: 30591992
Cytopathology. 2014 Jun;25(3):190-8
pubmed: 24329613
Diagn Pathol. 2010 Jan 26;5:9
pubmed: 20181018
Int J Environ Res Public Health. 2016 Apr 22;13(4):442
pubmed: 27110805
J Clin Endocrinol Metab. 2005 May;90(5):2512-21
pubmed: 15713710
J Indian Med Assoc. 2009 Feb;107(2):72-7
pubmed: 19585813
Thyroid. 2021 May;31(5):772-786
pubmed: 33256569
Cancers (Basel). 2022 Dec 22;15(1):
pubmed: 36612045
Endocrinol Metab (Seoul). 2022 Oct;37(5):703-718
pubmed: 36193717
J Clin Endocrinol Metab. 2008 Apr;93(4):1390-3
pubmed: 18198227
Mod Pathol. 2007 Oct;20(10):1095-102
pubmed: 17660800
JAMA Oncol. 2016 Aug 1;2(8):1023-9
pubmed: 27078145
Prostate Cancer Prostatic Dis. 2012 Dec;15(4):320-8
pubmed: 22370725
Ann Surg. 2004 Sep;240(3):425-36; discussion 436-7
pubmed: 15319714
Medicina (Kaunas). 2021 Nov 14;57(11):
pubmed: 34833464
J Clin Invest. 2004 Apr;113(8):1234-42
pubmed: 15085203
Endocrinol Metab Clin North Am. 1995 Dec;24(4):761-801
pubmed: 8608779
J Mol Diagn. 2006 Sep;8(4):490-8; quiz 528
pubmed: 16931590
Ann Surg. 2002 May;235(5):656-62; discussion 662-4
pubmed: 11981211
Endocr Relat Cancer. 2010 Jul 28;17(3):691-708
pubmed: 20668010

Auteurs

Prasanna V Perumal (PV)

Pathology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, IND.

Neelaiah Siddaraju (N)

Pathology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, IND.

Sunil K Saxena (SK)

ENT, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, IND.

Soundravally Rajendiran (S)

Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, IND.

Ramachandra V Bhat (RV)

Pathology, Indira Gandhi Medical College and Research Institute (IGMC & RI), Puducherry, IND.

Classifications MeSH